Abstract
A two-center phase I trial published in the New England Journal of Medicine shows safety and feasibility of locally administered oncolytic herpes simplex virus-1 virus plus 5Gy radiation for progressive pediatric high-grade gliomas. Patients seemed to have an unusually good clinical course and showed immune activation in post-treatment tissues.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
